Pulmonary fibrosis is a chronic disease in which lung tissue becomes inflamed, scarred, and stiff. The cause is often unknown, but the resulting damage can be deadly. A Yale School of Medicine study published Nov. 18 in Science Translational Medicine could be the first step toward reversing the disease.
Patients with pulmonary fibrosis can be treated with antifibrotics. However, these medications are not curative; they only slow the progression of the disease.
"As a result, patients tend to die earlier than they should," says Erica Herzog, MD, PhD, John Slade Ely Professor of Medicine (Pulmonary) at Yale School of Medicine. For 26 years, Herzog has cared for patients with pulmonary fibrosis in her clinic while researching a potential cure. "We don't fully understand how people get lung fibrosis or why they get worse," she says.
An earlier study in the Herzog Lab showed that the immune system plays a role in the progression of lung fibrosis. She and her colleagues found that during fibrosis, a group of immune cells called macrophages signal the brain to send nerves into the lungs.
The current understanding is that the immune system is communicating with all the different cells in the lung and sensing that there's injury. And in an attempt to heal the injury, they start producing mediators and behaving in such a way that these fibroblasts get activated."
Erica Herzog, MD, PhD, John Slade Ely Professor of Medicine (Pulmonary), Yale School of Medicine
To study how healthy fibroblasts-cells that form connective tissue in the body-stimulate fibrosis or scar tissue, Herzog and her colleagues simulated pulmonary fibrosis in mice. Using whole-lung tissue imaging, they saw the scar formation. As things unfolded, they observed that sympathetic nerves, which are part of the fight-or-flight response, grew into the area of the fibrotic tissue.
"These are regions that nerves aren't in typically," Herzog says. To confirm that the nerves had anything to do with the fibrosis, the researchers knocked out a gene involved in the development and vitality of sympathetic nerves. Doing so prevented the progression of the fibrosis, the researchers found, confirming that these nerves were indeed closely intertwined with the disease.
Hypertension drug suppresses pulmonary fibrosis
In healthy lungs, sympathetic nerves can be found primarily in the large and central regions of the airway. Meanwhile, Herzog and her colleagues found that fibrotic lungs had nerves innervating the small and peripheral regions. "It appears that during fibrosis, the lung becomes rewired," Herzog says.
One thing stood out about how these sympathetic nerves were distributed: In both healthy and fibrotic lungs, the sympathetic nerves accumulate in regions where the protein alpha-smooth muscle actin (α-SMA) is abundant.
In 1987, the U.S. Food and Drug Administration (FDA) approved a medication called terazosin that decreases the production of α-SMA. Because α-SMA controls muscle contraction, terazosin-also known as an alpha-blocker-was given to patients with hypertension to relax the smooth muscles in the blood vessels, which in turn lowers blood pressure.
Since the presence of sympathetic nerves (which trigger fibrosis) and α-SMA are linked, "It raises the possibility that if we treat the patients with alpha-blockers, then we can reduce progression and improve their disease," Herzog says.
When the researchers treated fibroblasts from patients with terazosin, they found the scarring response was suppressed.
"This provides a rationale for clinical trials to assess the repurposing of FDA-approved alpha-blockers for the treatment of lung fibrosis," Herzog says. "What we've discovered is a fundamental new mechanism for scar formation in the lung that can be used to understand the disease better, but more importantly, to potentially develop new ways to treat patients.
Current treatments for patients with pulmonary fibrosis are expensive, have many side effects, only slow progression in some, and do not help people live longer, explains Herzog. Meanwhile, many alpha-blockers are available in generic forms, safe, well tolerated, and covered by most insurance.
While the findings could help meet this critical need, there are many questions left to investigate, Herzog says. "We've only evaluated one type of cell-the fibroblasts-but really, multiple different cells and mechanisms are likely at play."
Herzog also noted that the characteristics of the cells that make up the disease tend to differ from person to person. "There's a significant divergence, which could explain why we see mixed treatment responses and why it's so difficult to treat this condition."
Her team is now investigating the role of other cells, such as immune and epithelial cells, in the progression of the disease and searching for ways to interrupt nerve growth in fibrotic regions of the lungs.
"We hope that our discovery could one day be used to help patients who are living with this disease," Herzog says.
Source:
Journal reference:
Ishikawa, G., et al. (2026). Noradrenergic input from sympathetic nerves to fibroblasts regulates lung fibrosis. Science Translational Medicine. DOI: 10.1126/scitranslmed.adw3631. https://www.science.org/doi/10.1126/scitranslmed.adw3631